Not recruiting
Study on the Safety and Immune Response of RSVPreF3 Vaccine for Respiratory Syncytial Virus in Adults Aged 60 and Above
Not recruitingRegistered drugNo placebo
Study on the Safety and Immune Response of RSVPreF3 Vaccine for Respiratory Syncytial Virus in Adults Aged 60 and Above
Registered drugNo placebo
Countries:
Finland
Finland- Participants:18–64 years · 65+ years
- Substances:Respiratory Syncytial Virus, Glycoprotein F, Recombinant, Stabilised In The Pre-Fusion Conformation, Adjuvanted With As01E
